Deerochanawong, J
[4] [5] Most patients taking GLP-1 receptor agonists will not experience ocular complications, though rare reports of other eye conditions exist with uncertain causality
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone-results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-nave patients with type 2 diabetes
The UK SmPCs for semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro), as well as their EMA European Public Assessment Reports (EPARs), document well-characterised GI side effect profiles that include nausea, vomiting, diarrhoea, constipation, and dyspepsia
Adverse Effects Aside from the debated increased risk of DR progression, a separate complication that has garnered widespread attention is the purported association of semaglutide with an increased risk of NAION, a vision-threatening condition